Observations placeholder

Nadolol (Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol) is a non-selective beta blocker used in the treatment of high blood pressure and chest pain - its only FDA approved uses.

“Additionally, however, it is often prescribed in the treatment of migraine headaches, adult attention deficit hyperactivity disorder, essential tremor, and Parkinson's disease.”  This arbitrary use causes problems.  You will see below that it has produced quite a number of Adverse medical reports, but we don’t know whether this was caused because the drug itself is generally a problem, or because it was mis-prescribed outside FDA uses.

Nadolol is a non-selective beta blocker; that is, it non-selectively blocks both beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and theoretically causing a decrease in heart rate and blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma – shortness of breath. “Because of its beta-2 activity, nadolol causes pulmonary bronchoconstriction and should be avoided in asthma patients”.

Nadolol is also used as a ‘preferred beta-blocker’  in the management of patients with LQTS for shortening of the QT interval and ‘prevention of ventricular arrhythmia’.  Since arrhythmia is caused by mineral imbalance or inappropriate pharmaceutical use, it is difficult to see how beta blockers help. 

“Patients whose heart rate is largely mediated by the sympathetic nervous system e.g. patients with congestive heart failure or myocardial infarct should avoid nadolol as it inhibits sympathetic function. Nadolol is also contraindicated in patients with bradycardia (slow heart rate) because of its tendency to cause bradycardia”.

Because nadolol, like other beta-2 blockers, inhibits the synthesis and release of glucose in response to hypoglycemia, it slows patients' recovery from acute hypoglycemic episodes.

“In a small study of 10 healthy individuals, green tea decreased the maximum plasma concentration and total concentration of Nadolol by over 85%. As such, it is suggested that green tea should be avoided when taking SLCO1A2 based drugs.”

On Sep, 1, 2014: 1,814 people who reported to have side effects when taking Nadolol are studied

Most common side effects by gender  :

On Aug, 25, 2014: 1,814 people reported to have side effects when taking Nadolol. Among them, 9 people (0.50%) have Hallucination.

• On Aug, 12, 2014: 1,814 people reported to have side effects when taking Nadolol. Among them, 1 people (0.06%) has Hallucination, Auditory.
• On Sep, 5, 2014: 1,814 people reported to have side effects when taking Nadolol. Among them, 5 people (0.28%) have Hallucination, Visual.
• On Sep, 5, 2014: 1,814 people reported to have side effects when taking Nadolol. Among them, 2 people (0.11%) have Hallucinations, Mixed.